Infantile Hemangioma - CHU Sainte-Justine - SAAC

More documents

Recommendations

Info

Consultant Pierre FabreDermatology andChair DSMB Hemangiol TrialI will not be discussing any results from thistrial nor draw conclusions from it.I will be discussing non-FDA approvedmedications
Overview• Which hemangiomas need treatment• Natural History• When to treat – new information on growth• When hemangiomas go away• Treatment with beta-blockers• Meta-analysis of Rx with propranolol in ~ 1200 pts.• Consensus guidelines for propranolol use• Topical beta-blockers
Page 1: Infantile Hemangiomas:Approach and
Page 5 and 6: How do we decidewhich hemangiomasto
Page 7 and 8: Risk of Segmentals• Segmental hem
Page 9 and 10: Residual skin changes inuntreated h
Page 11 and 12: Very Early Growth:Birth 1 year 2yea
Page 13 and 14: Very Early Growth:Study usingparent
Page 15 and 16: Timing of Initiation of Treatment~1
Page 17 and 18: Reevaluationat age 3 to 4 years•
Page 19 and 20: Propranolol as RxLéauté-Labrèze
Page 21 and 22: Results of Systematic Review• Res
Page 23 and 24: Propranolol ConsensusGuidelinesDrol
Page 25 and 26: Monitoring - All Patients• The pe
Page 27 and 28: Caveat• This information is based
Page 29 and 30: What about TopicalBeta-Blockers?
Page 31 and 32: Topical Beta-Blockers:Experience in

Infantile Hemangioma - CHU Sainte-Justine - SAAC

Create successful ePaper yourself

Delete template?

Save as template?